"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease "
2022-06-27
عنوان الدراسة
"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease "
داعم الدراسة
Janssen-Cilag International NV
دواء الدراسة
Guselkumab
رقم بروتوكول الدراسة
CNTO1959CRD3001
حالة الدراسة
Ongoing
موقع الدراسة
KAMC
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。